Chemed (CHE) Upgraded to Buy: Here's What You Should Know

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 9, 2025

Chemed Corporation to Present at the BofA Securities 2025 Virtual Home Care Conference

CINCINNATI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2025 Virtual Home Care Conference on Tuesday, December 9, 2025, at 1:20 PM (ET). The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations).

GlobeNewsWire • Dec 4, 2025

Chemtrade Logistics Income Fund (CHE.UN:CA) Q3 2025 Earnings Call Transcript

Chemtrade Logistics Income Fund ( CHE.UN:CA ) Q3 2025 Earnings Call November 12, 2025 10:00 AM EST Company Participants Rohit Bhardwaj - VP of Finance & CFO Scott Rook - CEO, President & Trustee Conference Call Participants Nikolai Goroupitch Joel Jackson - BMO Capital Markets Equity Research Ben Isaacson - Scotiabank Global Banking and Markets, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Chemtrade Logistics Income Fund Third Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference call over to Rohit Bhardwaj, Chief Financial Officer.

Seeking Alpha • Nov 12, 2025

Chemed Corporation (CHE) Presents at UBS Global Healthcare Conference 2025 Transcript

Chemed Corporation ( CHE ) UBS Global Healthcare Conference 2025 November 11, 2025 2:00 PM EST Company Participants Michael Witzeman - Executive VP, Controller, Principal Accounting Officer & CFO Kevin McNamara - CEO, President & Director Joel Wherley - CEO, President & Chief Operating Officer Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Presentation Albert Rice UBS Investment Bank, Research Division All right. Thanks, everyone.

Seeking Alpha • Nov 11, 2025

Wall Street Analysts Predict a 32.69% Upside in Chemed (CHE): Here's What You Should Know

The mean of analysts' price targets for Chemed (CHE) points to a 32.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Nov 11, 2025

Chemed Corporation Declares Quarterly Dividend of 60 Cents

CINCINNATI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company's capital stock, payable on December 5, 2025, to shareholders of record as of November 17, 2025. This is equal to the dividend paid in August 2025. This represents the 218th consecutive quarterly dividend paid by Chemed in its 54 years as a public company.

GlobeNewsWire • Nov 7, 2025

Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference

CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at approximately 2:00 p.m. (ET) at the PGA National Resort in Palm Beach Gardens, Florida.

GlobeNewsWire • Nov 4, 2025

Schwartz Offloads 28,000 Chemed (CHE) Shares Valued at $13 Million

Schwartz Investment Counsel sold 28,771 shares of Chemed Corporation; estimated transaction value of approximately $13.03 million based on average third-quarter 2025 pricing Trade represented 0.4% of Schwartz's reportable U.S. equity assets under management as of Q3 2025 Post-trade stake: 111,033 shares valued at $49.71 million as of Q3 2025 Chemed now accounts for 1.67% of AUM as of September 30, 2025, which places it outside the fund's top five holdings

The Motley Fool • Nov 2, 2025

EULAV Asset Management Unloads $13 Million of Chemed (NYSE: CHE) Stock: Should Investors Sell Too?

EULAV Asset Management sold 28,313 shares of Chemed, estimated at ~$12.82 million. The transaction value represents 0.3% of EULAV Asset Management's 13F reportable assets under management (AUM) as of Q3 2025.

The Motley Fool • Oct 30, 2025

Chemed Corporation (CHE) Q3 2025 Earnings Call Transcript

Chemed Corporation ( CHE ) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Holley Schmidt Kevin McNamara - CEO, President & Director Michael Witzeman - Executive VP, Controller, Principal Accounting Officer & CFO Joel Wherley - CEO, President & Chief Operating Officer Conference Call Participants Benjamin Hendrix - RBC Capital Markets, Research Division Brian Tanquilut - Jefferies LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Presentation Operator Good morning, and thank you for standing by. Welcome to the Chemed Corporation Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Oct 29, 2025